Clinical Trial Update: Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) [Phase 1]

View source ↗

Summary

A Phase 1 multiple-dose trial of MK-4334 in participants with Alzheimer's disease and mild cognitive impairment has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• MK-4334

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Alzheimer's Disease, Mild Cognitive Impairment | Phase 1 | Status: WITHDRAWN